<DOC>
	<DOCNO>NCT00854620</DOCNO>
	<brief_summary>Determine time-to-progression ( TTP ) escalate dose schedule subject progressive metastatic renal cell carcinoma treat sorafenib</brief_summary>
	<brief_title>Safety Toxicity Study Sorafenib Patients With Kidney Cancer</brief_title>
	<detailed_description>Sorafenib administer 28-day cycle . Sorafenib dose escalation cycle : - Cycle 1 : 400 mg BID - Cycle 2 : 600 mg BID - Cycle 3+ : 800 mg BID Within subject dose escalation maximum dose dependent observe tolerability . Dose escalation occur acceptable tolerability demonstrate subject .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically cytologicallyconfirmed metastatic unresectable renal cell carcinoma ( RCC ) . 2. must component conventional clear cell renal carcinoma . 3 . No one prior systemic therapy . 4 . No prior vascular endothelial growth factor receptor agent . 5 . Prior palliative radiotherapy metastatic lesion ( ) permit , provide subject least one measurable and/or evaluable lesion ( ) irradiate . 6 . All major surgery type and/or radiotherapy must complete least 4 week prior Day 1 dosing . Patients must recover surgery and/or radiotherapy toxicity prior Day 1 dosing . 7 . Measureable disease RECIST criteria 8 . Karnofsky performance status least 70 % ECOG 2 9 . Ability give write informed consent 10 . At least 18 year old 11 . Negative pregnancy test within 7 day Day 1 dosing ( female subject childbearing potential ) 12 . Sexually active fertile subject must agree use accepted method contraception course study 3 month thereafter . 13 . ANC least 1,500/uL 14 . Platelet count least 100,000/uL 15 . AST/ALT 2.5 time upper limit normal ( ULN ) 16 . Alkaline phosphatase 2.5 x ULN 17 . Serum bilirubin 1.5 x ULN 18 . Amylase/Lipase within normal range 19 . Urinalysis 1+ protein 20 . Serum creatinine 1.5 x ULN 21 . No active ischemia ECG 22 . Echocardiogram MUGA ejection fraction least 40 % 1 . Ongoing hemoptysis 2 . Cerebrovascular accident within 12 month 3 . Peripheral vascular disease claudication le 1 block 4 . History clinically significant bleed 5 . Malignancy true papillary/sarcomatoid feature without clear cell component 6 . Chromophobe 7 . Oncocytoma 8 . Collecting duct tumor 9 . Transitional cell carcinoma 10 . Deep venous thrombosis pulmonary embolus within one year consent 11 . Ongoing need fulldose oral parenteral anticoagulation . Low dose coumadin ( 1 mg ) maintenance catheter patency daily prophylactic aspirin allow 12 . Subjects evidence current central nervous system ( CNS ) metastases 13 . MRI CT scan brain ( contrast , possible ) within 28 day prior Day 1 dose 14 . Significant cardiovascular disease define congestive heart failure ( New York Heart Association Class II , II IV ) 15 . Angina pectoris require nitrate therapy 16 . Myocardial infarction within last 6 month 17 . Uncontrolled hypertension ( define blood pressure least 160 mmHg systolic least 90 mmHg diastolic medication ) 18 . Ongoing requirement systemic corticosteroid therapy ( except replacement therapy adrenal insufficiency ) . Topical and/or inhale steroid allow . 19 . Uncontrolled psychiatric disorder 20 . Delayed heal wound , ulcer , and/or bone fracture 21 . Prior malignancy ( EXCEPTIONS : adequatelytreated basal cell squamous cell skin cancer cancer chemotherapy complete &gt; 5 year ago patient diseasefree &gt; 5 year ) 22 . Pregnant 23 . Currently lactate 24 . Currently use St John 's Wort ( herb )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>